Indivior Posts Record Q3: SUBLOCADE $267M, EPS $1.12, Merger Closes Nov 2
INDV sits 42% above its 52-week low of $24.28.
Summary
Indivior reported record Q3 2026 results — revenue up 13% to $356 million, SUBLOCADE up 22% to $267 million, and adjusted EBITDA up 76% to $211 million — and said its merger with Supernus is on track to close November 2, 2026.
Key Events · Earnings and Guidance · INDV
-
Record Q3 Revenue and SUBLOCADE Growth
Total net revenue was $356 million, up 13% year-over-year, as total SUBLOCADE net revenue rose 22% to a record $267 million; U.S. SUBLOCADE grew 24% to $252 million on 17% dispense unit volume growth.
-
Record Profit and EBITDA Margin
GAAP net income was $137 million ($1.12 diluted EPS) versus $42 million a year ago, and adjusted EBITDA rose 76% to $211 million, a 59% margin, up 2,100 basis points year-over-year.
-
Merger Closing Set for November 2
Indivior shareholders approved the Supernus merger in October 2026; the deal is expected to close November 2, 2026, with the combined company trading as SUPN beginning November 3, 2026.
-
Guidance Stands Until Closing
Indivior remains on track for full-year 2026 guidance of $1,295 million to $1,365 million in net revenue and $700 million to $740 million in adjusted EBITDA, which ceases to apply once the merger closes.
Analysis · INDV · Life Sciences
Days before shareholders are handed Supernus stock, Indivior delivered its strongest quarter yet. Revenue rose 13% to $356 million, SUBLOCADE grew 22% to $267 million, and adjusted EBITDA jumped 76% to $211 million at a 59% margin. Net income of $137 million ($1.12 per diluted share) versus $42 million a year ago shows the cost cuts are flowing straight to the bottom line, and $332 million of cash and investments carries into the merger. The practical takeaway: the November 2 closing now looks locked in. Shareholders approved the deal in October, the $8.13 special dividend is tied to closing, and guidance stops applying once the combined company begins trading as SUPN on November 3. What remains for holders is the exchange ratio and the dividend record date of October 30, not Indivior's standalone numbers.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDV was trading at $34.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $24.28 to $42.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.